



# Pembrolizumab (Keytruda®)

Lungenkarzinom, nicht-kleinzellig (NSCLC) » PD-L1  $\geq 50\%$ , mono »  
Erstlinie

Empfehlungen der Fachgesellschaft zum Einsatz neuer Arzneimittel

## **Herausgeber**

DGHO Deutsche Gesellschaft für Hämatologie und  
Medizinische Onkologie e.V.  
Bauhofstr. 12  
10117 Berlin

Geschäftsführende Vorsitzende: Prof. Dr. med. Claudia Baldus

Telefon: +49 (0)30 27 87 60 89 - 0

[info@dgho.de](mailto:info@dgho.de)

[www.dgho.de](http://www.dgho.de)

## **Ansprechpartner**

Prof. Dr. med. Bernhard Wörmann  
Medizinischer Leiter

## **Quelle**

[www.onkopedia.com](http://www.onkopedia.com)

Die Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen entbinden die verantwortliche Ärztin / den verantwortlichen Arzt nicht davon, notwendige Diagnostik, Indikationen, Kontraindikationen und Dosierungen im Einzelfall zu überprüfen! Die DGHO übernimmt für Empfehlungen keine Gewähr.

# Inhaltsverzeichnis

<b>1 Pembrolizumab, NSCLC, PD-L1 <math>\geq</math>50%, mono, first line .....</b>	<b>2</b>
---	----------

# Pembrolizumab (Keytruda®)

**Dokument:** Fact Sheet

**Spezifizierung:** Lungenkarzinom, nicht-kleinzellig (NSCLC) » PD-L1 ≥50%, mono » Erstlinie

**Stand:** Juli 2021

## 1 Pembrolizumab, NSCLC, PD-L1 ≥50%, mono, first line

**Pembrolizumab, NSCLC, PD-L1 ≥50%, mono, first line**

onkopedia				Facts	Appraisal	EU Approval 2016																																																																															
<b>Parameter</b>	<b>Results<sup>14</sup></b>	<b>HR<sup>15</sup></b>	<b>p value</b>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 10%;">Evidence (LoE)</td> <td style="width: 10%;">5</td> <td style="width: 10%;">4</td> <td style="width: 10%;">3b</td> <td style="width: 10%;">3a</td> <td style="width: 10%;">2c</td> <td style="width: 10%;">2b</td> <td style="width: 10%;">2a</td> <td style="width: 10%;">1b</td> <td style="width: 10%;">1a</td> </tr> <tr> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td style="background-color: black;"></td> <td></td> </tr> <tr> <td>Clinical benefit (ESMO MCBS)</td> <td colspan="9"></td> </tr> <tr> <td></td> <td>1</td> <td>2</td> <td>3</td> <td>4</td> <td>5</td> <td colspan="4"></td> </tr> <tr> <td></td> <td></td> <td></td> <td></td> <td style="background-color: yellow;"></td> <td></td> <td colspan="4"></td> </tr> <tr> <td></td> <td colspan="9"> <span style="color: blue;">■</span> curative    <span style="color: yellow;">■</span> non-curative                 </td> </tr> <tr> <td colspan="4"> <b>Patients</b> first line, PD-L1 (TPS) ≥50%  <b>Trial</b> KEYNOTE-024, phase 3  <b>Randomisation</b> 1 : 1  <b>N<sup>1</sup></b> 305  <b>New Therapy</b> Pembrolizumab  <b>Control</b> Platin-containing chemotherapy  <b>Publication</b> DOI:10.1056/NEJMoa1606774                 </td> <td colspan="3"> <b>Additional benefit (G-BA)</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 10%;">lower</td> <td style="width: 10%;">not proven</td> <td style="width: 10%;">not quantifiable</td> <td style="width: 10%;">minor</td> <td style="width: 10%;">considerable</td> <td style="width: 10%;">major</td> </tr> <tr> <td></td> <td></td> <td></td> <td></td> <td style="background-color: black;"></td> <td></td> </tr> </table> </td> </tr> </table>			Evidence (LoE)	5	4	3b	3a	2c	2b	2a	1b	1a											Clinical benefit (ESMO MCBS)											1	2	3	4	5																<span style="color: blue;">■</span> curative <span style="color: yellow;">■</span> non-curative									<b>Patients</b> first line, PD-L1 (TPS) ≥50% <b>Trial</b> KEYNOTE-024, phase 3 <b>Randomisation</b> 1 : 1 <b>N<sup>1</sup></b> 305 <b>New Therapy</b> Pembrolizumab <b>Control</b> Platin-containing chemotherapy <b>Publication</b> DOI:10.1056/NEJMoa1606774				<b>Additional benefit (G-BA)</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 10%;">lower</td> <td style="width: 10%;">not proven</td> <td style="width: 10%;">not quantifiable</td> <td style="width: 10%;">minor</td> <td style="width: 10%;">considerable</td> <td style="width: 10%;">major</td> </tr> <tr> <td></td> <td></td> <td></td> <td></td> <td style="background-color: black;"></td> <td></td> </tr> </table>			lower	not proven	not quantifiable	minor	considerable	major						
Evidence (LoE)	5	4	3b				3a	2c	2b	2a	1b	1a																																																																									
Clinical benefit (ESMO MCBS)																																																																																					
	1	2	3				4	5																																																																													
	<span style="color: blue;">■</span> curative <span style="color: yellow;">■</span> non-curative																																																																																				
<b>Patients</b> first line, PD-L1 (TPS) ≥50% <b>Trial</b> KEYNOTE-024, phase 3 <b>Randomisation</b> 1 : 1 <b>N<sup>1</sup></b> 305 <b>New Therapy</b> Pembrolizumab <b>Control</b> Platin-containing chemotherapy <b>Publication</b> DOI:10.1056/NEJMoa1606774				<b>Additional benefit (G-BA)</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 10%;">lower</td> <td style="width: 10%;">not proven</td> <td style="width: 10%;">not quantifiable</td> <td style="width: 10%;">minor</td> <td style="width: 10%;">considerable</td> <td style="width: 10%;">major</td> </tr> <tr> <td></td> <td></td> <td></td> <td></td> <td style="background-color: black;"></td> <td></td> </tr> </table>			lower	not proven	not quantifiable	minor	considerable	major																																																																									
lower	not proven	not quantifiable	minor	considerable	major																																																																																

Legende:

<sup>1</sup> N - number of patients

<sup>2</sup> RR - remission rate, in %

<sup>3</sup> PFS - progression-free survival in months

<sup>5</sup> OS - overall survival in months

<sup>7</sup> SAE - serious adverse events, CTCAE grade 3/4

<sup>14</sup> results for control, results for new therapy

<sup>15</sup> hazard ratio for new therapy